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Abstract
Hepatitis E virus (HEV) is a pathogen that causes hepatitis 
worldwide. Molecular studies have identified HEV RNA in 
blood products although its significance is not understood. 
This study was undertaken to characterize HEV genomes in 
asymptomatic plasma donors from Sweden and Germany 
lacking anti-HEV. Complete open reading frames (ORFs) 
were obtained from HEV strains in 5 out of 18 plasma donors 
who tested positive for HEV RNA. All strains had CUG as the 
start codon of ORF3, while 147 GenBank strains all had AUG 
as the start codon (p < 0.0001). This substitution was found 
in both interrelated and unrelated strains belonging to dif-
ferent phylogenetic clades. The HEV strains from the sero-
negative plasma donors had no other substitution in com-
mon, which may be why the CUG substitution seems to ex-
plain the seronegativity. © 2018 The Author(s) 
Published by S. Karger AG, Basel
Hepatitis E virus (HEV) is a positive strand RNA virus 
of approximately 7.2 kb belonging to the family Hepeviri-
dae. Strains infecting humans belong to five genotypes 
(HEV1-HEV4 and HEV7) within Orthohepevirus A [1]. 
HEV is mainly transmitted by the faecal-oral route, but 
blood transmission may occur [2]. HEV1 and HEV2 
cause sporadic cases or large waterborne outbreaks in de-
veloping countries, while HEV3 and HEV4 have zoonot-
ic reservoirs, mainly pigs and wild boar, and probably 
cause most endemic human HEV3 infections by faecal-
oral spread [2, 3]. There are nine HEV3 subtypes in two 
major phylogenetic clades, 3I by subtypes abchij, and 3II 
by efg [4, 5].
HEV3 is the common genotype in Europe [2], where 
the number of notified cases increases yearly. Serological 
studies have shown relatively high rates of HEV exposure 
in blood donors [6, 7] and molecular analysis has demon-
strated HEV-RNA in blood and blood products [7–12], 
such as in Sweden where about 1/8,000 blood donations 
has HEV RNA [10]. It has been shown that blood donors 
All sequences reported from this study have been deposited in Gen-
Bank; accession No. MH377721–27.
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with HEV RNA may be anti-HEV negative for up to 48 
days, before seroconversion [8, 11]. There are studies 
showing a low risk of transmission of HEV from HEV 
RNA-positive blood donations [13], but also that it is cost 
effective to screen blood products for HEV to minimize 
hepatitis E posttransfusion [14]. Five European countries 
have introduced HEV RNA screening of blood products 
based on this [15].
Seventy per cent of HEV3 infections are subclinical 
[16]. However, the infection may even be fulminant [2]. 
It may also cause chronic hepatitis in immunosuppressed 
individuals [17, 18], in whom viral RNA can be detected 
for 6 months before seroconversion [18]. During a resolv-
ing infection, HEV RNA can be detected in serum prior 
to and 1–2 weeks after the onset of illness and for anoth-
er 2 weeks in faeces [19]. Immune response against HEV 
can be detected shortly after viremia and may persist for 
at least 5–6 years [19].
The HEV genome has three open reading frames, 
ORF1–ORF3, and two short non-coding regions, a 
5′-methylguanine-cap and a 3′-poly A-tail [20]. ORF1 is 
the longest ORF and is only present in the genomic RNA. 
ORF2 and ORF3 are expressed by the same bicistronic 
subgenomic RNA.
ORF1 encodes a non-structural polyprotein of 1,693 
amino acids (aa) with several putative domains implicat-
ed in viral replication, pathogenesis, and host tropism 
[20]. Among these are a methyltransferase [20], a Y-do-
main with unknown function, a papain-like protease 
[20], a hypervariable region with a proline-rich domain 
[21], an X-domain or ADP-Ribose-binding domain des-
ignated as a macro domain [20], a helicase with nucleo-
tide and MgCl2-binding sites [20], and the C-terminal 
longest domain encoding the RNA-dependent RNA 
polymerase (RdRP).
ORF2 encodes a 660-aa-long protein which is pro-
cessed by cleavage of a signal sequence of 22 aa at the N-
terminus [22], and thereafter self-associates into viral 
capsids that can be glycosylated [23]. The N-terminal 111 
residues are responsible for packaging of the viral RNA 
genome and residues 112–660 for forming virus-like par-
ticles. This latter region has the S-domain forming the 
capsid shell, the P1-domain, which together with the S-
domain forms the icosahedral capsid symmetry, and the 
P2-domain, which protrudes out from the viral capsid 
[24] and is important for receptor binding and has im-
mune-dominant epitopes.
ORF3 is the smallest ORF and encodes a 113-aa-long 
multifunctional phosphoprotein. In patient sera it is 
bound to viral particles associated with cellular mem-
branes [25]. It has been proposed to affect the host in-
flammatory response [26, 27]. At the N-terminal part of 
the protein two hydrophobic domains are located, D1 
and D2, where D1 is important for cytoskeleton associa-
tion [28]. Part of D1 and D2 act as an ion channel impor-
tant for viral egress [29]. Two other regions, P1 and P2, 
are proline-rich domains. P1 has motifs homologous to 
kinase substrates, and Ser79 in this region has been shown 
to be phosphorylated in vitro [28], and when phosphory-
lated shown to be involved in the binding of ORF3 to 
non-glycosylated viral capsids. The P2 region contains a 
ProSerAlaPro motif (residues 104–107) important for the 
formation of membrane-associated HEV particles and 
together with another Pro95XXPro98 motif critical for vi-
ral egress [30].
A junction region (JR) located between ORF1 and 
ORF3 contains a cis-reactive element (CRE) that may 
serve as a promoter for subgenomic mRNA [31]. This 
CRE is 15 nucleotides long and conserved in all HEV ge-
notypes infecting humans. Part of the 3′-end of ORF2 and 
the 3′UTR-region of the genome form a secondary struc-
ture predicted to be another CRE essential for HEV rep-
lication [32].
Complete HEV3 genomes have mainly been sequenced 
from patients with acute, fulminant, and chronic HEV, or 
from pigs and wild boar. Even if clinical HEV infections 
in immunocompetent hosts are well characterised, less is 
known regarding strains causing asymptomatic often un-
diagnosed infections in immunocompetent individuals. 
In this study, we have therefore characterized near com-
plete HEV RNA genomes from 4 Swedish and 1 German 
HEV RNA-positive but seronegative plasma donors. 
They were selected from 18 plasma donors who were pos-
itive for HEV RNA during the screening process for plas-
ma donations at Octapharma AB (Stockholm, Sweden) 
between 2010 and 2013.
The 18 samples were tested for IgM antibodies to hep-
atitis E (anti-HEV IgM) and IgG (anti-HEV IgG) by com-
mercial enzyme-linked assays (HEV IgM Dia.pro and 
HEV IgG Dia.pro, Diagnostic BioProbes, Milan, Italy). 
Only 3 had both anti-HEV IgG and IgM, 2 had borderline 
values for anti-HEV IgG, and the remaining 13 were neg-
ative (Table 1). All 5 donors with a sequenced HEV strain 
were anti-HEV negative (Table 1).
Nucleic acids were extracted from 250 μL of plasma 
from the 18 donors as described [3]. Viral RNA was de-
tected in 17 by an in-house TaqMan qPCR assay [3]. A plas-
mid with the target region was used to set the threshold to 
measure the Ct value for product quantification. Five mi-
crolitres of extracted RNA were reversely transcribed to 
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cDNA and detected by PCR [3]. Sets of primers were used 
to amplify the complete genome of five selected HEV strains 
(online suppl. Table S1; for all online suppl. material, see 
www.karger.com/doi/10.1159/000491926). The first PCR 
mixtures consisted of 5 μL of cDNA added to a 45-μL mas-
ter mix containing 200 μM of dNTPs (Roche Diagnostics), 
400 nM of each primer, 1× Advantage GC-2-PCR-Buffer, 
500 μM of GC-Melt and 1× Advantage-GC-2-Polymerase 
Mix (Clontech Laboratories, Mountain View, CA, USA). A 
second nested PCR was performed with reaction mixtures 
containing the same reagents at the same concentrations as 
the first PCR, but with different primers and 1 μL of the first 
amplified product as a template. Human sera with HEV 
RNA were used as positive controls, and nuclease-free wa-
ter as a negative control. The amplification products were 
purified and sequenced as described [3].
Part of the 5′-half of the genomes was difficult to am-
plify by PCR with primers with sequences present in the 
strains. Therefore, the amplification was performed with 
a mixture of primers with known HEV sequences mixed 
with random primers and sequenced by next generation 
sequencing (NGS). A total of 5 μL of cDNA was used in 
triplicate as the template in a touch-up gradient PCR us-
ing specific primers in a first round amplification with 50 
μL of reaction mix containing 6.5 μL of cDNA, 1× Taq 
buffer (Applied Biosystems), 2 mM of MgCl2 (Applied 
Biosystems), 0.5 mM dNTP (Sigma-Aldrich), 1 U Taq 
polymerase (Roche Diagnostics), and 0.8 μM of each 
primer. The PCR reaction was performed for 1 cycle at 
94  ° C for 3 min, followed by 12 cycles of touch-up PCR 
with 94  ° C for 30 s, 20  ° C for 190 s (2  ° C increase per cycle), 
followed by 30 cycles of 94  ° C for 30 s, 48  ° C for 30 s, and 
68  ° C for 2 min, and with 5 min of final extension at 68  ° C.
Libraries were built on the PCR products using an Ion-
Plus-Fragment-Library Kit on Library BuilderTM System 
(ThermoFisher, Waltham, MA, USA) according to the 
Table 1. Designation and characterization of samples from 18 plasma donors sequenced in partial ORF1
Strain No. Designation Country of
origin
Belonging
to clade
Anti-HEV IgG
sample/cut-off
Anti-HEV IgM
sample/cut-off
HEV RNA, 
copies/mL
2 BD15-75 Germany 3II 0.83 0.75 23,100
22 BD15-84 Sweden 3II 0.19 0.05 1,500
62 BD15-71 Sweden 3c/i 1.64 0.25 10,700
63 BD15-81 Sweden 3c/i 0.17 0.06 4,650
66 BD15-88 Sweden 3c/i 0.18 0.05 13,400
BD15-72 Sweden 3II 1.56 9.2 900
BD15-73 Sweden 3II 0.29 0.11 <100
BD15-74 Sweden 3II 0.24 0.16 350
BD15-76 Germany 3II 6.47 2.88 700
BD15-77 Germany 3c/i 1.16 0.70 3,700
BD15-78 Sweden 3II 0.43 0.99 <100
BD15-79 Germany 3c/i 0.35 0.51 18,700
BD15-80 Sweden 3II 0.73 0.13 93,000
BD15-82 Sweden 3I 0.20 0.08 57,000
BD15-83 Sweden 3II 0.29 0.17 <100
BD15-85 Sweden 3II 0.19 0.03 6,000
BD15-86 Germany 3c/i 1.73 3.80 1,000
BD15-87 Germany 3II 0.17 0.04 5,700
Strains with numbers were subjected to complete genomic sequencing. Values considered reactive for anti-HEV-IgG and IgM are 
shown in bold. Cut-off was calculated according to the manufacturer. Sample/cut-off values >1 and <1.7 are considered as borderline 
values and shown as regarded negative [40].
(For figure see next page.)
Fig. 1. UPGMA dendrogram based on 356 nucleotides of partial 
ORF1 in 165 HEV genotype 3 sequences. The branches with 3II 
and 3i/c strains are enlarged. The accession numbers, host, and 
origin of the strains are given at the nodes. Strains from 13 plasma 
donors without anti-HEV are marked in red, and three strains 
from plasma donors with anti-HEV are marked in blue. The five 
strains of which near complete genomes were sequenced are 
marked with arrows. One strain from a seronegative plasma donor 
belonged to clade 3I and is not shown in the enlarged tree. The two 
major HEV3 clades, 3I and 3II, and subtypes are indicated on the 
branches. Colors refer to the online version.
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manufacturer. Newly built libraries were amplified for 8 
cycles and purified with AMPureXP-beads (Beckman 
Coulter, Brea, CA, USA) and thereafter analysed and 
loaded on an ion 318 chip and sequenced on an IonTor-
rent PGM with an Ion-PGM-Hi-Q-View-Sequencing Kit 
(ThermoFisher) as previously described [33]. The se-
quences obtained were imported into a CLC Genomic 
Workbench 9.5.1 (Qiagen, Hilden, Germany) and anal-
ysed as previously described [33]. The contigs and single-
ton reads were blasted against known HEV genomes us-
ing BLASTn, and a cut-off for E-value of 10–3 for signifi-
cant hits. Between 7,194 and 19,175 contigs > 100 bp could 
be matched to HEV. About 80% of the complete genomes 
for all five strains were obtained by combining Sanger se-
quencing and NGS. The remaining regions and sequenc-
es obtained by NGS were confirmed by PCR with primer 
sequences obtained by NGS and Sanger sequencing. By 
using these techniques complete ORF1-ORF3 regions 
and between 69 and 88% of the non-coding regions were 
obtained for all five strains.
Analysis of partial ORF1 of seventeen strains from the 
donors revealed that the strains belonged to both major 
clades, thirteen to clade 3II, one to clade 3I, and three 
were on the branch formed by subtypes 3c/i (Fig. 1). This 
was confirmed when complete genomes were compared.
Near-complete genomes, 7,202–7,227 nucleotides, 
were obtained for five strains (No. 2, 22, 62, 63, and 66). 
These were aligned with 147 complete HEV3 genomes 
from GenBank (online suppl. Table S2). Genetic distanc-
es were calculated using the Hasegawa-Kishino-Yano al-
gorithm in the DNADIST program in the PHYLIP pack-
age version 3.65 [34] with a transition/transversion ratio 
of 9.14, and gamma correction with alpha 0.27. Phyloge-
netic trees were constructed as previously described [3].
All five sequenced genomes had the three predicted 
ORFs. ORF1 was 5,112–5,115 nucleotides long. Strain 2 
had a 3-nucleotide insertion encoding a proline739 in the 
hypervariable region.
The predicted structure of the reverse complement se-
quence of 58 nucleotides between nucleotides 5102 and 
5159 (FJ998008) forming the JR of the genome differed 
between the strains (online suppl. Fig. S1). Within this 
region 8 nucleotides, GAATAACA, were conserved as in 
all other Orthohepevirus A strains.
ORF1 encoded 1,704–1,705 aa residues. Strain 66 had 
a unique substitution, Leu138Phe, in the methyl transfer-
a
ORF3
D1 cytosceleton binding D1
D2 hemopexin binding                                    D2/transmembrane region P1 P2 SH3-binding viral egressP1 phosphorylation MAKP
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ...
clade 5          15         25         35         45         55         65         75         85         95        105        115  
65   3c/i MNNMFCALPM GSPCALGLFC CCSSCFCLCC PRHHTASRLA AVVGGAAAVP AVVSGVTGLI PSPSPSPIFI QPTPSPPTSY RNPGLELALD SHPAPSAPLG VTSPCAPPLS HVVDLPQLGL RR*
62   3c/i    ---------L ---------- ---------- ---RP----- V--------- ---------- ---------- -------M-F ---------- -R-------- ---------P P--------- --*
63   3c/i ---------L A--------- --T------- ---QP----- ---------- ---------- ---------- ----L—-M-F ---------- ---------- ---------P –A-------- --*
66   3c/i ---------L ---------- ---------- ---RP----- ---------- ---------- ---------- -------ML- ---------- ------S--- ---------- ---------- --2    
3II ---------L ---------- ---------- ---RP----- V--------- ---------- ---------- -----L---- H--------- ---V-L---- ----S----P P--------- --*
22 3II ---------L ---------- ---------- ---RP----- ---------- ---------- L--------- ----L----- H--------- -R---L---- A---S---PP P--N------ --*
b
-6     -3                           -1                                            -2-1      +4 
65 GGGUGGAAUG AAUAACAUGU UUUGUGCAUU GCCCAUGGGA UCACCAUGCG
62 ----A----- ---------- ---------- ----C----- ----------
63 ---A------ ---------- ---------- ----C---C- ----------
66 ----A----- ---------- ---------- ----C----- ----------
2 --U------- ---------- ---------- ----C----- --------T-
22 --U------- ---------- ---------- ----C----- --G-----T-
Fig. 2. a Deduced aa sequence of ORF3 protein for five strains from 
the plasma donors aligned with strain 65 from a patient with 
chronic hepatitis E. The different domains, D1, D2, P1, P2, and a 
transmembrane region are indicated. The three methionine resi-
dues are marked in bold, with the third also underlined, and as-
sumed to be used as the start of ORF3. This residue is leucine in 
strains from the plasma donors. Unique substitutions are marked 
with bold red letters. The three PXXP regions, of which the third 
“PSAP” is assumed to be important for the phosphorylation of 
ORF3, are boxed in blue. All GenBank strains belonging to the 3II 
clade expressed the 104PSAP107 motif, while strains belonging to 
3c/i expressed PCAP in this region. Three of these strains ex-
pressed PSAP at residues 95–98. b Nucleotide sequence. The three 
start codons in frame for ORF3 are boxed in blue. In the strains 
from the plasma donors, the third start codon is CUG, the most 
common noncanonical start codon. The AUG start codon for 
ORF2 is boxed in grey. The Kozak recognition nucleotides are 
marked in red. The optimal sequence is GCCRCCAUGG, with the 
most important nucleotides in bold. Colors refer to the online ver-
sion.
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ase domain. The Y domain was highly conserved and had 
the predicted N-linked glycosylation site at positions 
363–365. The Gly-triplet proposed to be the substrate for 
proteolysis of the ORF1 protein in the X domain, at resi-
dues 825—827, was conserved in all sequenced strains 
[35]. All six predicted motifs in the 233-aa-long helicase 
domain between residues 971 and 1205 were also con-
served. In this domain, two strains, 63 and 66, expressed 
one unique substitution each, Ile1165Arg and Ala-
1071Cys, respectively.
In the region coding for the RdRP encompassing 487 
aa of the C-terminal part of ORF1, six of the eight pre-
dicted motifs were conserved for the sequenced strains, 
including the GlyAspAsp (GDD) site at residues 1561–
1563. Two unique substitutions were expressed, As-
n1233Asp in strain 2 and Ala1269Ser in strain 22.
The deduced ORF2 proteins had the three predicted 
N-linked glycosylation sites at residues 137–139, 310–
312, and 562–564. Three strains, 22, 62, and 66, had five 
unique substitutions in ORF2, two of which were adja-
cent to the C-terminal region of the assumed neutralisa-
tion epitope between residues 578 and 607, Ala608Val in 
strain 22 and Ile581Val in strain 62.
The gene product of ORF3 is assumed to be 113 resi-
dues long for HEV3. The only substitution in common 
for the strains of the 5 seronegative plasma donors was a 
substitution to CUG of the third of three AUG codons in 
the frame located in the JR (Fig. 2a). AUG is present in all 
known HEV3 strains and is considered the start codon for 
ORF3 [36]. The second AUG codon in the frame for 
ORF3 is located downstream of ORF1, the first within 
ORF1.
The second hydrophobic region of ORF3, D2, between 
residues 37 and 62, overlapped with a proposed trans-
membrane region at residues 41–60 identified in the se-
quenced strains. Strains 22, 63, and 66 expressed one to 
two unique substitutions each in ORF3. A Ser79Leu sub-
stitution in strain 66 may eliminate the phosphorylation 
site of its deduced ORF3 protein. This strain had a unique 
Ala97Ser substitution, which may serve the function of 
being phosphorylated in place of Ser79. Three of the 5 
plasma donors shared the relatively uncommon mutation 
of Ser105Cys. Both the Ser79 and the Cys105 in the 
pORF3 may potentially affect the formation of viral cap-
sids or egress (Fig. 2b).
As mentioned, all five sequenced genomes had CUG 
instead of AUG as the start codon for pORF3 [36, 37], 
while all 147 HEV3 genomes retrieved from GenBank 
had an AUG at this position (p < 0.0001, Fisher exact test). 
This AUG is the only one of the three AUG codons in the 
frame for ORF3 in HEV1–3 genomes with a strong Kozak 
consensus sequence. In addition, the other AUGs have 
been shown to be dispensable for the expression of ORF3 
[36]. CUG is quite frequently used as a start codon for 
RNA viruses; these are mainly plant viruses [38], but also 
a few animal viruses, such as Sendai virus [38], as well as 
for some eukaryotic genes, although it is less efficient than 
AUG [39].
A lower expression of ORF3 may alter functions shown 
for this protein on the innate immune response [26] and 
type I interferon production [27]. The substitution of the 
third AUG to CUG may not only downregulate the ex-
pression of the ORF3 protein, but also cause structural 
changes of HEV RNA in regions with regulatory func-
tions, since the CRE within the JR region is assumed to 
act as a promoter for the subgenomic mRNA [31, 37]. 
Therefore, the CUG substitution may also affect the ex-
pression of ORF2. This may render the viral strains less 
immunogenic or less virulent with a relatively lower level 
of replication and protein expression. It may also affect 
the virus ability to transmit and cause infection, since the 
pORF3 has been shown to be important for viral egress. 
This might mean that there is lower risk for hepatitis E 
transmission during the viraemic, although a seronega-
tive state supports a study from Denmark [13]. Serocon-
version to anti-HEV may occur after reversion of the 
ORF3 start codon to AUG. This would also result in a 
structural reversal of the promoter of ORF2 and ORF3 
subgenomic mRNA, which in turn can lead to an in-
creased expression of these proteins. This is in support of 
a study from the Netherlands showing cost effectiveness 
of blood screening for HEV RNA [14].
Previously assumed functions of the ORF3 protein 
have been identified through high expression of its prod-
uct in cell culture. Less has been demonstrated on the 
functions of this protein in its natural host. This study 
shows the need for genomic sequencing of strains direct-
ly isolated from patients to understand the biology of 
HEV, since cell propagated virus may not always mirror 
the infection in the natural host. Further studies should 
investigate if strains from seronegative blood donors with 
HEV RNA are infectious and if the change in the start 
codon for ORF3 and the promotor for the subgenomic 
mRNA may also influence the ability of the virus to spread 
and cause infection, although it seems apparent that the 
non-canonical start codon for ORF3 and its accompany-
ing effect on the subgenomic promotor will explain the 
absence of immune response in the seronegative plasma 
donors.
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